> ## Content Index
> Fetch the complete content index at: https://www.theinvestorsociety.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Evvy Lands US$40M to Measure What IVF Clinics Have Been Skipping
- URL: https://www.theinvestorsociety.com/evvy-lands-us-40m-to-measure-what-ivf-clinics-have-been-skipping/
- Published: 2026-09-18T00:00:04.000Z
- Updated: 2026-09-18T00:00:04.000Z
- Author: The Editor
- Tags: Western Hemisphere

Evvy, the New York women's health company that sequences the vaginal microbiome from an at-home swab, said on September 15, 2026 that it had raised an oversubscribed US$40 million Series B led by Catalio Capital Management. New investors Rethink Impact, Muse Capital and Alumni Ventures joined, alongside existing backers including the LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Foreground Capital, Ingeborg and Flywheel Ventures. Jacob Vogelstein, co-founder of Catalio, is the lead investor on the round.

The company was founded in 2021 by Chief Executive Officer Priyanka Jain along with Laine Bruzek and Pita Navarro. It sells a CLIA and CLEP certified mail-in test that sequences vaginal microbes, routes the results through registered clinicians and returns a diagnosis with a treatment plan through a patient portal, covering conditions from bacterial vaginosis and urinary tract infections to symptoms tied to perimenopause. Evvy says it has served more than 100,000 patients in the United States, has about 3,000 practitioners on its platform, reaches a diagnosis in more than 90% of symptomatic patients and has cut bacterial vaginosis recurrence by roughly half in patients on its care pathway. The new capital funds an expansion into fertility, where Evvy is running a prospective in vitro fertilization study with US Fertility, plus AI diagnostic models built on its dataset.

## Market Context

Evvy's bet is that the asset is the data, not the test. The company says its research arm has produced more than a dozen peer-reviewed publications and abstracts, identified previously undescribed subtypes of bacterial vaginosis and catalogued hundreds of vaginal microbiome genomes that were not in existing references. That matters because the clinical standard for diagnosing bacterial vaginosis, the Amsel criteria and Nugent scoring, dates to the 1980s and 1990s, and recurrence rates after standard antibiotic treatment have long run above 50% within a year. A dataset that links sequencing results to symptoms, interventions and outcomes is the input an AI diagnostic needs, and it is the piece the category has been missing.

The funding environment is the other half of the story. PwC has projected that the broader women's health market could reach US$600 billion by 2030, and early-stage investors have funded the category heavily since 2020\. Growth-stage capital has been slower to follow, in part because companies like Evvy sit awkwardly between a consumer brand and a life sciences business, and investors have pushed founders to pick one. Catalio, which invests at the intersection of biotech and data, is a notable lead precisely because it is buying the research side rather than the direct-to-consumer funnel. Evvy also distributes through employer benefit platforms including Carrot and Parsley, which gives it a second channel that does not depend on consumer acquisition costs.

## What Stands Out

> "You can't build precision medicine for women on datasets that never adequately measured female biology in the first place." — Priyanka Jain, Co-Founder and CEO, Evvy

## Regional Relevance

For the United States, the round sits on top of a structural data problem in American medicine. Women were not required to be included in federally funded clinical research until the National Institutes of Health Revitalization Act of 1993, and the gap in baseline biological measurement has persisted into the era of algorithmic diagnosis. A commercial company assembling a large, longitudinal, consented dataset on a biomarker that has been almost entirely absent from the clinical record is doing something the public research system has not. If the IVF study holds up, the immediate market is the roughly 100,000 US patients who go through fertility treatment each year and the payers and employers underwriting it.

The second layer is competitive. LabCorp's venture arm is an investor, which suggests a path from direct-to-consumer kit into the national reference lab channel, where the volume and reimbursement live. That would move Evvy from a subscription wellness product into standard diagnostics, a far larger but far slower market governed by CPT codes and payer coverage decisions rather than by marketing.

The risk running underneath both is that the science is still being built. The link between vaginal microbiome composition and infertility, preterm birth, IVF success and gynecological cancer is supported by third-party research but not settled, and Evvy is raising growth capital to prove causation in areas where the field currently has association.

## The Other Side

**Does the dataset translate into reimbursed clinical practice?** A 90% diagnosis rate in symptomatic patients is a strong product metric, but payers reimburse against validated clinical guidelines, and those guidelines still rest on decades-old criteria. Changing them takes prospective trials, professional society endorsement and time that a venture-backed company measures in rounds.

**Can a consumer brand and a research platform share one balance sheet?** Jain has been explicit that investors pushed her to choose. The consumer business funds sample collection, and the research business is the long-term value, but they compete for the same capital, and consumer health brands have repeatedly found that acquisition costs rise faster than repeat purchase rates.

**What is the defensibility once sequencing gets cheap?** The test itself is not proprietary technology. What protects Evvy is the accumulated linkage between sequencing data and outcomes, and that advantage holds only if competitors, including the reference labs that also sit on its cap table, do not assemble comparable datasets through existing patient volume.

## Sources & Transparency

- [Evvy raises $40M as it seeks to further women's health research with vaginal microbiome data](https://techcrunch.com/2026/09/15/evvy-raises-40m-as-it-seeks-to-further-womens-health-research-with-vaginal-microbiome-data/?ref=theinvestorsociety.com)
- [Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women's Health](https://www.businesswire.com/news/home/20260915847589/en/Evvy-Raises-$40M-Series-B-to-Scale-AI-Powered-Precision-Diagnostics-Care-Platform-for-Womens-Health?ref=theinvestorsociety.com)
- [Exclusive: Evvy raises $40 million Series B](https://fortune.com/2026/09/15/evvy-series-b-womens-health-vaginal-microbiome-research/?ref=theinvestorsociety.com)
- [Evvy raises $40M to expand precision medicine for vaginal health](https://www.fiercehealthcare.com/finance/evvy-raises-40m-expand-precision-medicine-vaginal-health?ref=theinvestorsociety.com)
- [Evvy Raised $40 Million For Data On Women's Bodies To Fill Scientific Gap](https://www.forbes.com/sites/geristengel/2026/09/16/evvy-raised-40-million-for-data-on-womens-bodies-to-fill-scientific-gap/?ref=theinvestorsociety.com)
- [Evvy raises $40M from Catalio Capital to take its vaginal microbiome data into fertility](https://techfundingnews.com/evvy-raises-40m-from-catalio-capital-to-take-its-vaginal-microbiome-data-into-fertility/?ref=theinvestorsociety.com)